Critical Comparison: Oncobiologics (NASDAQ:OTLK) versus enGene (NASDAQ:ENGN)

enGene (NASDAQ:ENGN) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Risk and Volatility

enGene has a beta of -0.28, meaning that its stock price is 128% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Profitability

This table compares enGene and Oncobiologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Oncobiologics	N/A	N/A	-276.35%

Insider & Institutional Ownership

64.2% of enGene shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for enGene and Oncobiologics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2	8	4	0	2.14
Oncobiologics	1	4	2	0	2.14

enGene presently has a consensus price target of $11.05, indicating a potential upside of 549.73%. Oncobiologics has a consensus price target of $4.65, indicating a potential upside of 514.75%. Given enGene’s higher probable upside, research analysts clearly believe enGene is more favorable than Oncobiologics.

Earnings and Valuation

This table compares enGene and Oncobiologics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30 million	($2.17)	-0.78
Oncobiologics	$1.35 million	83.25	-$62.42 million	($1.17)	-0.65

Oncobiologics has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Summary

enGene beats Oncobiologics on 6 of the 11 factors compared between the two stocks.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.